Quick Answer
SAB Biotherapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
SAB Biotherapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $0.00 -100.0% |
$1.32M -40.9% |
$2.24M -90.6% |
$23.90M -60.7% |
$60.88M +10.2% |
$55.24M |
| Revenue (ASC 606) | $0.00 -100.0% |
$1.32M -40.9% |
$2.24M -90.6% |
$23.90M -60.7% |
$60.88M +10.2% |
$55.24M |
| Net Income | $13.27M +138.9% |
-$34.11M +19.2% |
-$42.19M -125.1% |
-$18.74M -9.3% |
-$17.14M -185.2% |
$20.12M |
| Diluted EPS | -$0.79 +78.5% |
-$3.68 +51.8% |
-$7.64 -77.3% |
-$4.31 -584.1% |
-$0.63 -185.1% |
$0.74 |
| Total Assets | $172.81M +291.0% |
$44.20M -47.3% |
$83.94M +22.6% |
$68.49M -15.6% |
$81.14M +43.5% |
$56.54M |
| Cash and Equivalents | $10.50M +18.0% |
$8.90M -84.3% |
$56.57M +152.4% |
$22.41M -32.5% |
$33.21M +163.3% |
$12.61M |
| Stockholders Equity | $151.49M +483.4% |
$25.97M -54.7% |
$57.30M +38.9% |
$41.26M +7.0% |
$38.55M -1.2% |
$39.01M +407.0% |
| R&D Expense | $34.35M +13.6% |
$30.25M +83.2% |
$16.52M -54.7% |
$36.44M -36.3% |
$57.18M +104.9% |
$27.91M |
| Operating Income | -$48.95M -14.1% |
-$42.91M -12.7% |
-$38.08M -31.7% |
-$28.92M -115.9% |
-$13.39M -165.2% |
$20.56M |
| Shares Outstanding | 47.61M +412.5% |
9.29M +0.7% |
9.23M -78.5% |
42.96M -1.2% |
43.49M +67.4% |
25.97M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2024 | $263.1K | +207.7% | -72.1% |
| Revenue (ASC 606) | June 30, 2024 | $263.1K | +207.7% | -72.1% |
| Net Income | September 30, 2025 | $45.45M | +539.1% | +549.3% |
| Diluted EPS | September 30, 2025 | -$0.21 | +81.2% | +80.7% |
| Total Assets | September 30, 2025 | $183.45M | +241.0% | +508.9% |
| Cash and Equivalents | September 30, 2025 | $29.42M | +220.8% | +696.9% |
| Stockholders Equity | September 30, 2025 | $165.07M | +347.3% | +1273.8% |
| R&D Expense | September 30, 2025 | $8.97M | +14.5% | +28.2% |
| Operating Income | September 30, 2025 | -$12.68M | -12.1% | -30.3% |
| Shares Outstanding | September 30, 2025 | 47.49M | +414.6% | +411.1% |
- SAB Biotherapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
- SAB Biotherapeutics, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- SAB Biotherapeutics, Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
- SAB Biotherapeutics, Inc. showed a decrease of -100.0% in Revenue (ASC 606) compared to the prior fiscal year.
- SAB Biotherapeutics, Inc. reported Net Income of $13.27 million for fiscal year 2025.
- SAB Biotherapeutics, Inc. showed an increase of +138.9% in Net Income compared to the prior fiscal year.
- SAB Biotherapeutics, Inc. reported Diluted EPS of $0.79 per share (loss) for fiscal year 2025.
- SAB Biotherapeutics, Inc. showed an increase of +78.5% in Diluted EPS compared to the prior fiscal year.
- SAB Biotherapeutics, Inc. reported Total Assets of $172.81 million for fiscal year 2025.
- SAB Biotherapeutics, Inc. showed an increase of +291.0% in Total Assets compared to the prior fiscal year.
- SAB Biotherapeutics, Inc. reported Cash and Equivalents of $10.50 million for fiscal year 2025.
- SAB Biotherapeutics, Inc. showed an increase of +18.0% in Cash and Equivalents compared to the prior fiscal year.
- SAB Biotherapeutics, Inc. reported Stockholders Equity of $151.49 million for fiscal year 2025.
- SAB Biotherapeutics, Inc. showed an increase of +483.4% in Stockholders Equity compared to the prior fiscal year.
- SAB Biotherapeutics, Inc. reported R&D Expense of $34.35 million for fiscal year 2025.
- SAB Biotherapeutics, Inc. showed an increase of +13.6% in R&D Expense compared to the prior fiscal year.
- SAB Biotherapeutics, Inc. reported Operating Income of -$48.95 million for fiscal year 2025.
- SAB Biotherapeutics, Inc. showed a decrease of -14.1% in Operating Income compared to the prior fiscal year.
- SAB Biotherapeutics, Inc. reported Shares Outstanding of 47.61 million shares for fiscal year 2025.
- SAB Biotherapeutics, Inc. showed an increase of +412.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: